Skip to content

Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)

Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI) to Provide Human Connection Through Communication

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07357428
Acronym
CONNECT-ONE
Enrollment
2
Registered
2026-01-22
Start date
2026-03-31
Completion date
2032-01-01
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis, Cervical Spinal Cord Injury, Dysarthria, Neuromuscular Disease, Stroke, Tetraplegia/Tetraparesis

Keywords

BCI, ALS, Paradromics, speech, dysarthria, neural injury, progressive neuromuscular disease, stroke, assistive technology, communication device, brain computer interface

Brief summary

The Connect-One Study is an early feasibility study to obtain preliminary device safety information for the Connexus Brain-Computer Interface (BCI). The Connexus BCI is intended to be used as: (1) an assistive communication device to decode imagined language correlates and speech for patients with impaired communication as a result of severe loss of voluntary motor control; and (2) to provide control of computer devices for individuals with severe loss of voluntary motor control of the upper extremity.

Interventions

DEVICEConnexus Brain-Computer Interface

The Connexus Brain Computer Interface is an implantable brain-computer interface.

Sponsors

Paradromics
Lead SponsorINDUSTRY
University of Michigan
CollaboratorOTHER
University of California, Davis
CollaboratorOTHER
Massachusetts General Hospital
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of a progressive neuromuscular disease or a neurological injury. * Clinical diagnosis of anarthria or severe dysarthria. * Wheelchair dependent with severely impaired upper limb function. * Has a reliable method of communication and the ability to read and understand the English language. * Has a study care partner (e.g. caregiver or multiple caregivers) for the duration of the study. * Lives within a 4-hour radius of a study site.

Exclusion criteria

* Cognitive impairment or psychiatric illness that could impact the ability to comply with study requirements, as determined by the Study Investigator. * Co-morbidities or an ongoing chronic medical condition that would impair the ability to comply with study requirements. * The presence of another implanted device, like a pacemaker, deep brain stimulator, or implantable pulse generator. * Requires, or is expected to require regular MRI scans for on-going medical conditions. * In the opinion of the Study Investigator, the patient is not an appropriate candidate for the study, for reasons that could place the patient at undue risk or otherwise result in non-compliance with the study requirements.

Design outcomes

Primary

MeasureTime frameDescription
Primary Safety: Number of Subjects With Device Related Adverse EventsUp to 12 months post-implantDevice Related Adverse Events: Number of subjects with device-related adverse events

Secondary

MeasureTime frameDescription
Long-Term Safety: Number of Subjects With Device Related Adverse EventsUp to 6 years post-implantDevice Related Adverse Events: Number of subjects with device-related adverse events

Countries

United States

Contacts

CONTACTParadromics Clinical Team
clinical-team@paradromics.com(512) 559 4120

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 15, 2026